- After quarantining a suspect product, a pharmacy investigates with its trading partners and cannot verify the product's legitimacy. DSCSA classifies the product as illegitimate. Within what timeframe must the pharmacy notify the FDA?
Answer: Within 24 hours of making the determination that the product is illegitimate.
Under DSCSA, once a pharmacy determines that a product is illegitimate -- meaning it has been confirmed as counterfeit, diverted, stolen, or intentionally adulterated -- the pharmacy must notify the FDA within 24 hours of making that determination. B correctly states this timeframe. A is incorrect because the 24-hour clock runs from the illegitimacy determination, not from the initial quarantine. C is incorrect because 30 days far exceeds the 24-hour requirement. D is incorrect because FDA notification is mandatory, not optional, upon confirmation of illegitimacy.
- Under DSCSA, which of the following definitions best describes a suspect product?
Answer: A product suspected of being counterfeit, diverted, stolen, adulterated, or unauthorized for distribution.
Under DSCSA, a suspect product is one that a trading partner reasonably believes may be counterfeit, diverted, stolen, intentionally adulterated, or otherwise unfit, or that was introduced into commerce by an unauthorized party. C correctly states this definition. A is incorrect because price alone does not make a product suspect under DSCSA. B is incorrect because a voluntary recall creates a different set of obligations and is not the DSCSA definition of a suspect product. D is incorrect because temperature excursion triggers its own quality review but is not the DSCSA definition of suspect.
- Under DSCSA, what is the definition of an illegitimate product that triggers mandatory reporting?
Answer: A product confirmed as counterfeit, stolen, or intentionally adulterated.
DSCSA defines an illegitimate product as one confirmed to be counterfeit, diverted, stolen, or intentionally adulterated; a product that is the subject of a fraudulent transaction; or one introduced into commerce by an unauthorized trading partner. A correctly states this definition. B is incorrect because purchasing from an unlicensed distributor is a separate DSCSA violation from the definition of illegitimate product. C is incorrect because patient visual inspection is not a DSCSA verification standard. D is incorrect because recalled products trigger recall-specific obligations, not the DSCSA illegitimate product reporting framework.
- A pharmacy is investigating a suspect product and must decide whether to request enhanced due diligence documentation from its trading partner. Which of the following DSCSA documents would provide the most direct evidence of the product's supply chain legitimacy?
Answer: Transaction information and statement from the interoperable tracing system.
Under DSCSA's enhanced drug tracing requirements, the most direct evidence of a product's supply chain legitimacy is verification of the serialized product identifier through the interoperable electronic tracing system, supported by the transaction information and transaction statement accompanying the most recent transfer. These elements together allow the pharmacy to confirm that the specific product lot was handled through the authorized domestic supply chain. Note that transaction history as a standalone chain-of-custody document is no longer part of the current DSCSA tracing standard. D correctly identifies the current evidentiary framework. A is incorrect because trading partner licensure confirms authorization to distribute but does not verify this specific product lot's supply chain integrity. B is incorrect because a manufacturer approval announcement does not document this lot's chain of custody. C is incorrect because an internal quality checklist does not document the external supply chain history required by DSCSA.
- A pharmacy discovers that a controlled substance it received is confirmed counterfeit. Under DSCSA, the pharmacy must notify the FDA. What additional reporting obligation may apply under DEA regulations?
Answer: The pharmacy must file DEA Form 106 if the counterfeit discovery suggests significant loss or diversion of controlled substances.
If authentic controlled substances were replaced with counterfeits -- a form of diversion -- DEA Form 106 would be required to report the theft or significant loss of the authentic product. B correctly identifies this parallel DEA reporting obligation. A is incorrect because DSCSA FDA reporting and DEA loss reporting address different aspects of the same event and both may apply. C is incorrect because DEA Form 222 is used for ordering Schedule I and II controlled substances, not for reporting counterfeiting. D is incorrect because a 30-day written statement is not the required mechanism; DEA Form 106 is.
- A pharmacy's DSCSA verification system identifies a product's 2D barcode as not matching the manufacturer's database. The product is an oncology injectable with a current expiration date. Which of the following best describes the required action?
Answer: The pharmacy must not dispense any units of this product; a verification failure triggers suspect product status requiring quarantine and investigation regardless of expiration date or clinical appearance.
A 2D barcode verification failure triggers suspect product status under DSCSA regardless of expiration date or visual appearance. The product must be quarantined immediately and the investigation initiated. D correctly identifies this required response. A is incorrect because current expiration date does not override a DSCSA verification failure. B is incorrect because dispensing to observe patient reaction is a patient safety violation when a product has failed verification. C is incorrect because a manufacturer manual override of a verification failure is not a recognized DSCSA process.
- A pharmacist is approached by a patient who believes the medication she received last month from a different pharmacy was counterfeit based on its appearance and lack of expected effect. Which of the following best describes the pharmacist's appropriate response?
Answer: Advise the patient to report the suspected counterfeit medication to the dispensing pharmacy and FDA.
When a patient reports suspected counterfeit medication, the pharmacist should direct her to report it through appropriate channels -- the dispensing pharmacy, her prescriber, and FDA MedWatch -- and document the conversation. D correctly identifies these patient-protective actions. A is incorrect because social media complaints are not the appropriate regulatory reporting pathway. B is incorrect because counterfeit medications do occasionally enter the supply chain and dismissing the concern is professionally inappropriate. C is incorrect because insurance notification is not the relevant reporting pathway for suspected counterfeiting.
- A pharmacy's DSCSA suspect product investigation is still ongoing at the 30-day mark. The product remains quarantined. No definitive determination of legitimacy or illegitimacy has been made. Which of the following best describes the appropriate course of action?
Answer: Continue quarantine and notify the FDA if the product is deemed illegitimate; DSCSA requires determination before release.
Quarantine under DSCSA continues until a definitive determination of legitimacy or illegitimacy is reached, not until a set time period has elapsed. An inconclusive investigation after reasonable efforts results in the product being treated as illegitimate. C correctly identifies this standard. A is incorrect because passage of time does not authorize release from quarantine under DSCSA. B is incorrect because the absence of additional red flags during the investigation period is not the standard for release; verification of legitimacy is required. D is incorrect because DSCSA investigation extensions are not granted by state boards of pharmacy.
- A pharmacy receives notification from a trading partner that a product in the pharmacy's current inventory may be illegitimate. The pharmacy has dispensed 15 units to patients over the past week. Which of the following best describes the pharmacy's full set of obligations?
Answer: Quarantine remaining stock, investigate with trading partners, and notify FDA within 24 hours if confirmed.
DSCSA obligations require quarantine, investigation, FDA notification upon confirmation of illegitimacy, and trading partner notification. When patients have already received potentially illegitimate product, the pharmacy must also assess patient notification and clinical follow-up needs. A is incorrect because the pharmacy's responsibility extends to patients who have already received the product. B is incorrect because returning the product before completing the investigation does not satisfy DSCSA investigation obligations. C is incorrect because immediate destruction is not authorized and would eliminate evidence needed for the investigation.
- A pharmacy's DSCSA investigation determines a product in its inventory is illegitimate. Which of the following entities must the pharmacy notify?
Answer: The FDA and the product's trading partner.
DSCSA requires the pharmacy to notify the FDA within 24 hours of confirming illegitimacy and to notify the trading partner from whom the product was received. If patients have received the product, patient safety obligations also arise. D correctly identifies these required notifications. A is incorrect because state board and prescriber notification, while potentially appropriate, are not the DSCSA-mandated notification recipients. B is incorrect because DEA and law enforcement are not the DSCSA mandatory notification recipients for illegitimate products. C is incorrect because owner and insurer notification are internal business decisions, not DSCSA obligations.
- When a pharmacy identifies a suspect product under DSCSA, which of the following is the correct immediate action?
Answer: The pharmacy must immediately quarantine the suspect product, segregating it from dispensing stock to prevent it from reaching patients while the investigation proceeds.
The first required action under DSCSA upon identifying a suspect product is to quarantine it -- segregating it from dispensing stock so it cannot be dispensed to patients during the investigation. A correctly identifies this immediate obligation. B is incorrect because DEA is not the primary authority for DSCSA suspect product reporting; the FDA and trading partners are. C is incorrect because continuing to dispense a suspect product is a serious patient safety and regulatory violation. D is incorrect because returning the product before completing the investigation eliminates the ability to perform required DSCSA verification and documentation.
- A pharmacy must dispose of a product confirmed to be illegitimate under DSCSA. Which of the following best describes the required disposition process?
Answer: The pharmacy must quarantine the product, notify the FDA and trading partners, and dispose of it per regulatory requirements.
Once a product is confirmed illegitimate under DSCSA, the pharmacy must quarantine it to prevent dispensing, notify the FDA and affected trading partners, and dispose of it in a manner that removes it permanently from the supply chain. DSCSA does not require FDA authorization before each individual disposal act; rather, the pharmacy must follow applicable disposal regulations, which include DEA requirements if the product is a controlled substance. D correctly describes these obligations. A is incorrect because FDA notification alone does not authorize unrestricted disposal; applicable disposal regulations must be followed. B is incorrect because returning a confirmed illegitimate product to a trading partner would re-introduce it into commerce, which DSCSA prohibits. C is incorrect because immediate unilateral on-site destruction without following applicable disposal regulations may itself violate DEA or other requirements.
- A pharmacist receives a report from a patient who experienced a serious adverse reaction to what appears to be a subpotent medication. Upon examination, the pharmacist finds the lot number does not appear in the manufacturer's verification database. Which of the following best describes the initial required actions?
Answer: Quarantine the lot, report to FDA, investigate as suspect product, notify prescriber.
Multiple actions are simultaneously triggered: the product must be quarantined as a DSCSA suspect product, the adverse reaction should be reported to FDA MedWatch, a DSCSA investigation must be initiated, and the prescriber should be informed. A correctly identifies this comprehensive multi-action response. B is incorrect because dispensing additional units from a suspect lot while awaiting FDA guidance creates ongoing patient safety risk. C is incorrect because the DEA is not the appropriate authority for adulterated drug reporting absent a controlled substance connection. D is incorrect because insurance notification is not a relevant initial response to a suspect counterfeit drug adverse event.
- A pharmacy purchases medications from a secondary wholesaler offering significantly below-market prices. The distributor is licensed but the transaction information provided is incomplete. Which of the following best analyzes the DSCSA compliance concern?
Answer: Incomplete transaction information raises suspicion of counterfeit products; the pharmacy must verify legitimacy before dispensing.
Below-market pricing and incomplete supply chain documentation are significant red flags for potentially diverted or counterfeit products under DSCSA's enhanced drug tracing requirements. The pharmacy should treat these products as suspect, request complete transaction information and a transaction statement from the trading partner, and verify the serialized product identifier through the interoperable electronic tracing system before dispensing. C correctly identifies this risk-based analysis. A is incorrect because distributor licensure alone does not guarantee product legitimacy or DSCSA compliance. B is incorrect because an expiration date is not a substitute for supply chain traceability verification. D is incorrect because pricing strategies have no bearing on DSCSA compliance obligations.
- A community pharmacist discovers that a patient has been self-administering medications purchased from an online pharmacy that appears to be operating illegally. The patient shows the pharmacist the packaging, which lacks FDA-required labeling elements. Which of the following best describes the pharmacist's appropriate response?
Answer: The pharmacist should counsel the patient on risks of purchasing from unverified online pharmacies.
Patient counseling about the risks of illegal online pharmacies is appropriate and within the pharmacist's professional role. The pharmacist should inform the patient about risks of counterfeit or substandard products and encourage use of verified pharmacies. B correctly identifies this patient-protective response. A is incorrect because a pharmacist who is aware of a patient safety risk has a professional obligation to counsel. C is incorrect because pharmacists do not have authority to confiscate patients' medications. D is incorrect because a patient purchasing medications for personal use does not trigger DEA reporting.
- A wholesale distributor notifies a pharmacy that a lot of insulin it recently received may have been diverted from the legitimate supply chain. The pharmacy has not yet dispensed any units. What must the pharmacy do first?
Answer: Quarantine all units of the identified lot immediately to prevent dispensing while the investigation proceeds.
The immediate first step upon receiving a suspect product notification -- even before any units have been dispensed -- is quarantine. A correctly identifies this required action. B is incorrect because dispensing suspect product after notification would be a serious DSCSA violation and patient safety breach. C is incorrect because quarantine and investigation must precede any product return under DSCSA. D is incorrect because patient shortage notification is not the required first step when suspect product is identified; quarantine takes priority.
- Under DSCSA's enhanced drug tracing requirements, what documentation must accompany each prescription drug product transfer, and what are pharmacies' retention obligations?
Answer: Pharmacies must receive and retain transaction information and statements for 6 years for FDA inspection.
Under DSCSA's enhanced drug tracing framework, each transfer of a prescription drug product must be accompanied by transaction information and a transaction statement. Pharmacies must receive these documents, retain them for at least 6 years, and produce them for FDA inspection upon request. The enhanced tracing system also requires that serialized product identifiers be verifiable through the interoperable electronic product tracing system. Note that transaction history as a standalone chain-of-custody document is no longer part of the current DSCSA tracing requirement. A is incorrect because both transaction information and a transaction statement are required at the pharmacy level, not just the statement. C is incorrect because existing business relationships do not create exceptions to DSCSA documentation requirements. D is incorrect because 6 months is far below the 6-year retention requirement.
- A pharmacy staff member visually inspects a prescription product at receiving and notices the anti-counterfeiting hologram on the packaging appears to be a photocopy rather than an authentic hologram. Which of the following most accurately describes the appropriate response?
Answer: Quarantine the product and start a suspect product investigation per DSCSA guidelines.
A photocopied hologram is a significant anti-counterfeiting red flag that must trigger quarantine and DSCSA investigation. C correctly identifies this required response. A is incorrect because hologram variations do not explain a clearly photocopied authenticity feature. B is incorrect because logging without quarantine allows a potentially counterfeit product to be dispensed during the logging period. D is incorrect because returning the product to the delivery driver without documentation eliminates the chain-of-custody record needed for DSCSA investigation.
- A pharmacy's investigation of a suspect product cannot reach a definitive conclusion because the trading partner is unresponsive and batch records cannot be retrieved. Which of the following best analyzes this situation?
Answer: The pharmacy must treat the product as illegitimate and notify the FDA, without dispensing it.
If a pharmacy cannot verify a product's legitimacy after a good-faith investigation, the product must be treated as illegitimate. Inability to verify does not equal verification of legitimacy. B correctly identifies the risk-based approach required by DSCSA. A is incorrect because an inconclusive investigation does not authorize resumption of dispensing. C is incorrect because a prescriber's clinical need does not authorize dispensing a potentially counterfeit product. D is incorrect because a state board variance does not address federal DSCSA obligations.
- A pharmacist suspects a product may be counterfeit based on appearance but has not confirmed illegitimacy. Which of the following best describes the status of this product under DSCSA?
Answer: The product is a suspect product and must be quarantined and investigated with trading partners.
A product that a trading partner reasonably believes may be counterfeit is a suspect product under DSCSA. The required response is quarantine followed by investigation with trading partners to reach a determination of legitimate or illegitimate. A is incorrect because a suspected product must be investigated before being confirmed illegitimate. B is incorrect because suspicion triggers DSCSA obligations including quarantine; certainty is not required before acting. D is incorrect because immediate destruction without investigation and authorization is not the correct DSCSA response.
